Stockscreener 앱 받기
11.41
2.65%
-0.31
시간 외 거래:
11.41
전일 마감가:
$11.72
열려 있는:
$11.77
하루 거래량:
568.00K
Relative Volume:
0.53
시가총액:
$599.25M
수익:
$1.02B
순이익/손실:
$-757.20M
주가수익비율:
-0.773
EPS:
-14.76
순현금흐름:
$-257.90M
1주 성능:
-4.12%
1개월 성능:
+5.55%
6개월 성능:
+72.88%
1년 성능:
+31.30%
1일 변동 폭
$11.34
$11.85
1주일 범위
$11.16
$12.09
52주 변동 폭
$4.02
$13.41
Emergent Biosolutions Inc Stock (EBS) Company Profile
명칭
Emergent Biosolutions Inc
전화
240-631-3200
주소
300 PROFESSIONAL DR, GAITHERSBURG, MD
EBS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
11.41 | 615.53M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2024-03-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-08-29 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-04-10 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-10 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-04-29 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-11-08 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-05-05 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 개시 | The Benchmark Company | Buy |
| 2021-02-24 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-07-31 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-08-03 | 재확인 | Chardan Capital Markets | Buy |
| 2018-06-13 | 개시 | Argus | Buy |
| 2018-04-25 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2018-01-16 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Singular Research | Buy |
| 2016-04-15 | 개시 | Chardan Capital Markets | Buy |
| 2016-03-28 | 개시 | Singular Research | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2014-05-15 | 개시 | Summer Street Research | Buy |
| 2011-05-31 | 재확인 | WBB Securities | Strong Buy |
| 2011-01-10 | 재확인 | Wedbush | Outperform |
| 2010-11-05 | 재확인 | Wedbush | Outperform |
| 2010-08-18 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | 재확인 | Caris & Company | Buy |
모두보기
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site - The Manila Times
Emergent BioSolutions (NYSE: EBS) gains FDA OK for Winnipeg raxibacumab drug product site - Stock Titan
Energy Moves: Can Emergent BioSolutions Inc stock weather global recessionEarnings Growth Summary & Trade Opportunity Analysis Reports - moha.gov.vn
Emergent BioSolutions Inc Stock Analysis and ForecastEvening Star Patterns & Low Risk Capital Growth Plans - earlytimes.in
Emergent Biosolutions Q1 2025 Earnings Preview - MSN
EBS (NYSE: EBS) holder files Form 144 to sell 32,848 shares - Stock Titan
What makes Emergent BioSolutions Inc. stock appealing to growth investorsTrade Risk Report & AI Driven Stock Reports - Newser
Emergent Biosolutions Inc. $EBS Stock Holdings Increased by Geode Capital Management LLC - MarketBeat
How cyclical is Emergent BioSolutions Inc. (ER4) stock compared to rivalsMarket Risk Report & Free Reliable Trade Execution Plans - Newser
Will Emergent BioSolutions Inc. stock split again soonBull Run & Daily Risk Controlled Trade Plans - Newser
Will Emergent BioSolutions Inc. stock reach Wall Street targets2025 Big Picture & Advanced Swing Trade Entry Plans - Newser
How Emergent BioSolutions Inc. (ER4) stock behaves in tightening cyclesTrade Entry Summary & Daily Growth Stock Investment Tips - Newser
Will Emergent BioSolutions Inc. (ER4) stock extend growth storyJuly 2025 EndofMonth & Reliable Price Action Trade Plans - Newser
Published on: 2025-12-04 04:37:47 - Newser
Is Emergent BioSolutions Inc. (ER4) stock protected from inflationJuly 2025 Drop Watch & Low Drawdown Investment Strategies - Newser
Will Emergent BioSolutions Inc. (ER4) stock top growth indexesM&A Rumor & AI Driven Price Forecasts - Newser
EBS SEC FilingsEmergent Biosolutions Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Published on: 2025-12-03 01:19:03 - Newser
How Emergent BioSolutions Inc. stock compares to market leadersJuly 2025 Opening Moves & Technical Buy Zone Confirmations - Newser
Why ETFs are accumulating Emergent BioSolutions Inc. stockInsider Selling & Free Verified High Yield Trade Plans - Newser
Why Emergent BioSolutions Inc. stock is popular among millennialsInflation Watch & Weekly Top Stock Performers List - Newser
Why Emergent BioSolutions Inc. (ER4) stock remains top ratedDip Buying & Advanced Swing Trade Entry Alerts - Newser
Emergent BioSolutions (EBS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
What technical patterns form on Emergent BioSolutions Inc. (ER4) stock chartsPortfolio Value Report & Risk Controlled Swing Alerts - Newser
Why Emergent BioSolutions Inc. stock trades below fair value2025 Volatility Report & Weekly Chart Analysis and Guides - Newser
Will Emergent BioSolutions Inc. stock justify high valuationWatch List & Daily Market Momentum Tracking - Newser
Emergent Biosolutions (NYSE:EBS) Upgraded at Wall Street Zen - MarketBeat
Emergent Biosolutions Inc. diskutieren - sharewise.com
EBS (Emergent BioSolutions) Debt-to-EBITDA : 1.72 (As of Sep. 2025) - GuruFocus
Stock Report: Why Emergent BioSolutions Inc. stock is a must watch tickerEarnings Overview Report & Long-Term Investment Growth Plans - BỘ NỘI VỤ
Emergent BioSolutions up 10% on HC Wainwright buy initiation - MSN
Should Emergent BioSolutions Inc. (NYSE:EBS) Focus On Improving This Fundamental Metric? - 富途牛牛
Performance Recap: How risky is Emergent BioSolutions Inc. stock nowPortfolio Value Summary & Free Accurate Trade Setup Notifications - BỘ NỘI VỤ
Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt - simplywall.st
Emergent Biosolutions (NYSE:EBS) Downgraded to "Buy" Rating by Wall Street Zen - MarketBeat
With Emergent BioSolutions Stock Surging, Have You Considered The Downside? - Trefis
Emergent Biosolutions marks 10 years since FDA approval of NARCAN with Emmitt Smith - Traders Union
Why Emergent BioSolutions Inc. stock could outperform in 2025Weekly Profit Report & Advanced Swing Trade Entry Alerts - newser.com
Is Emergent BioSolutions Inc. stock undervalued at current price2025 Historical Comparison & AI Enhanced Trading Signals - newser.com
Is Emergent BioSolutions Inc. stock undervalued historicallyJuly 2025 News Drivers & Consistent Growth Stock Picks - newser.com
Why Emergent BioSolutions Inc. (ER4) stock is trending on social media2025 Institutional Moves & High Yield Stock Recommendations - newser.com
Will Emergent BioSolutions Inc. stock deliver consistent dividends2025 Earnings Surprises & Safe Swing Trade Setup Alerts - newser.com
Can Emergent BioSolutions Inc. stock deliver consistent EPS growth2025 Volume Leaders & Verified Entry Point Signals - newser.com
Will Emergent BioSolutions Inc. stock gain from green policiesJuly 2025 Opening Moves & Scalable Portfolio Growth Ideas - newser.com
How Emergent BioSolutions Inc. stock compares with tech leadersPortfolio Update Summary & Entry Point Strategy Guides - newser.com
How dovish Fed policy supports Emergent BioSolutions Inc. stockJuly 2025 Market Mood & High Accuracy Trade Signal Alerts - newser.com
Why millennials buy Emergent BioSolutions Inc. (ER4) stockPrice Action & AI Driven Stock Movement Reports - newser.com
Is Emergent BioSolutions Inc. stock resilient in recession scenariosPortfolio Gains Report & Daily Technical Forecast Reports - newser.com
Visual analytics tools that track Emergent BioSolutions Inc. performanceWeekly Investment Recap & Daily Stock Momentum Reports - newser.com
Understanding Emergent BioSolutions Inc.’s price movement2025 Major Catalysts & Weekly Sector Rotation Insights - newser.com
Emergent Biosolutions Inc (EBS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.48%
0.09%
자본화:
|
볼륨(24시간):